Momenta Pharmaceuticals, Inc. (MNTA)

[pollyvonwog]

For whatever reason, I assume this is why

Teva Copaxone Patent Reissue May Push Generics to ’15: Bernstein

Thursday, March 20, 2014 06:24 AM
by Sasha Damouni and Clyde Eltzroth
March 20 (Bloomberg) -- Teva is looking to have patent ’808 reissued, possibly delaying generic debut to 2015, Bernstein analyst Aaron Gal said in note.

Copaxone has two manufacturing patents (’808 and ’898) expiring September 2015 that aren’t listed in orange book
Bernstein and the market assumed “issue was over” and that from IP perspective, generics could enter market when the Copaxone formulation patents expire in May 2014
TEVA looking to add definition of molecular weight range as ’peak’ molecular weight
Copaxone is TEVA’s number 1 selling drug; 2014 estimates $3.31b (3 ests), falling to $2.64b (2 ests) in 2015: Bloomberg data
NOTE: On Nov. 23, TEVA sought to keep Copaxone patent coverage until 2015, challenged ruling that ends coverage in May